Figure 2.

Progression-free survival (PFS) of patients under olaparib treatment according to the pathogenicity of variants detected in tumors. (A): PFS of patients with benign (blue), VUS (black), and pathogenic (red) variants in tumors in response to olaparib. (B): PFS observed for patients with tumors containing BRCA1 (blue), BRCA2 (black), and other gene (red) variants in response to olaparib. (C): PFS observed for patients with tumors containing BRCA pathogenic variants (blue) or BRCA VUS (red). (D): PFS observed for patients with tumors containing pathogenic variants (blue) or VUS (red) in other genes. (E): The number of pathogenic variants or VUS in BRCA1, BRCA2 or other genes by site of origin. For all panels: the dashed line corresponds to 120 days.